Biotronik has announced the first observational results of the CERTITUDE registry, documenting real-world clinical outcomes of patients in the USA who use implantable loop recorders (ILR), pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronisation therapy (CRT-D) devices that have Biotronik Home Monitoring capability. Biotronik Home Monitoring is the only monitoring system approved by the US Food and Drug Administration (FDA) for early detection and as a replacement for device interrogation during in-office follow-ups.
While prior studies have shown an association between activity and outcomes, no studies had examined the temporal relationship between device-derived daily activity, a novel digital biomarker, and ventricular tachyarrhythmias (VT). The authors found temporal decline in device-derived activity following ventricular arrhythmias treated with a shock, but not in patients treated with anti-tachycardia pacing (ATP). Monitoring device-derived activity post-VT events with a shock could provide relevant clinical information and potentially warrant intensified treatment.
”The CERTITUDE registry represents a robust post-market database consisting of over 55,000 active patients monitored by the Biotronik Home Monitoring system. Our data analysis aimed to identify whether changes in activity predict VT, or conversely VT predict changes in activity,” said Valentina Kutyifa, associate professor of medicine at the University of Rochester Medical Center, Rochester, USA, who presented the data virtually at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual).”Between scheduled in-clinic appointments, this technology transmits remotely and leverages important clinically actionable data to improve physician comprehension of device therapy, results, and disease progression in a real-world context.”
The real-world observational study from ICD and CRT-D devices collected de-identified daily data on leads, arrhythmias, and vital signs such as activity within the normal course of medical care. Activity data was provided for 16,475 devices (9,732 ICDs, 6,743 CRT-Ds). The total period of follow-up was 18,355 years (5.6 million days with transmission). A total of 1,409 of the 2,636 VT episodes studied had a rate of >200 beats per minute (bpm), and 593 were treated with shock. Patients with VT episodes of >200 bpm who were given shock treatment showed a substantial decrease in activity after the VT event, with a median of -8.7% (IQR -24.6%; 7.3%, p<0.001). However, there was no decrease in activity until the VT exceeded 200 bpm (p=0.690). VT episodes with a heart rate of more than 200 bpm treated with ATP alone were not associated with reduction in activity before or after the episode.
Patient activity was measured with an accelerometer and was reported daily as a percentage active during the day. The initial event per device and seven-day activity windows were used to determine temporal changes in device-derived activity associated with treated VT. The baseline period was set at 31-38 days before the VT. Heart rate (≤200 bpm,>200 bpm) and therapy were used to classify VT occurrences (shock with or without ATP, ATP alone).
“The painless anti-tachycardia pacing feature options in Biotronik devices ensure optimal delivery to treat potentially life-threatening arrhythmias, avoiding unnecessary shocks,” said David Hayes, chief medical officer, Biotronik. “Our commitment to support a robust large-scale registry, such as CERTITUDE, is the type of clinical rigor that physicians have come to rely on and will propel us into the future in improving patients’ quality of life.”